Avipoxvirus (APV) infection is a highly contagious disease of birds and has been reported in more than 200 bird species, affecting both domesticated and free-ranging birds around the world. In New Zealand, at least three different strains of Avipoxvirus (APV) have been identified in a range of bird species.The pathogenicityof two APV strains isolated from wild birds in New Zealand, representing subclade A1 and subclade B1 were compared in zebra finches (Taeniopygia guttata). The efficacy of fowlpox vaccine at preventing clinical disease in passerines was also evaluated. Twenty-five zebra finches were divided into five groups (I-IV and a control group). Birds from Groups II and IV were vaccinated using fowl poxvirus vaccine prior to challenge. Subsequently two groups (I and II) were inoculated with a silvereye isolate (A1) and the other two groups (Group III and IV) were inoculated with a blackbird isolate (B1). Both inocula were previously propagated in chicken fibroblast cell culture. Birds in the control group were inoculated with sterile PBS. Skin thickness at the inoculation sites was measured and the development of additional skin lesions was monitored. Antibody development was measured by ELISA pre- and post virus inoculation. Both APV strains caused either swelling or hyperplasia at the inoculation site of non-vaccinated birds (4/5 in Group I and 5/5 in Group III). The swelling was milder and no foot lesions were observed in vaccinated birds before or after challenge with the silvereye or blackbird APV strains. These findings indicated that the fowlpox vaccine provided safe and appropriate protection for zebra finches exposed to the two wild APV strains and suggest that the vaccine has the potential to be used where APV threatens the captive management or translocation of endangered passerines.